Table 3.
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale-D Global Scores During the First 3 Hours of School at Baseline and During Treatment with the Three Formulations of Methylphenidate in the Intent-To-Treat Population
| na | Mean | SD | Median | |
|---|---|---|---|---|
| Baseline | 102 | 0.61 | 0.49 | 0.45 |
| Medikinet retard with a higher IR component and equivalent daily dose to Concerta | 99 | 0.60 | 0.56 | 0.44 |
| Medikinet retard with similar IR components and reduced daily dose | 104 | 0.67 | 0.55 | 0.59 |
| Concerta | 101 | 0.76 | 0.54 | 0.72 |
| Differencesb Medikinet retard in equivalent daily dose–Concerta | 93 | −0.15 | 0.44 | −0.08 |
| Differencesb Medikinet retard in reduced daily dose–Concerta | 98 | −0.07 | 0.42 | −0.03 |
a
n is the number of ADHD children and adolescents with complete data for the relevant variable.
b
Individual difference ignoring period effects.
ADHD=attention-deficit/hyperactivity disorder; SKAMP-D=German version of the Swanson, Kotkin, Agler, M-Flynn, and Pelham scale.